SCHEMBL47641

SCHEMBL47641

CC(CN(C)C)N(C)C(=O)c1cccnc1C(=O)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 2/20 0.39
CYP2C19 P33261 1/20 0.36
KDM4E B2RXH2 4/20 0.35
TSHR P16473 2/20 0.35
ALDH1A1 P00352 2/20 0.35
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35
ALOX15 P16050 1/20 0.35
BLM P54132 1/20 0.35
AGER Q15109 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HCRTR1 O43613 4/20 0.32
HCRTR2 O43614 4/20 0.32
ASPH Q12797 1/20 0.32
KDM8 Q8N371 1/20 0.32
P2RX7 Q99572 1/20 0.31
NAPRT Q6XQN6 1/20 0.31
HPGD P15428 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL47650 0.90 HDAC4 (0.38) HDAC4CYP2C19KDM4ETSHRALDH1A1
SCHEMBL18588755 0.79 POLR1A (0.42) HDAC4KDM4EALDH1A1KMT2A
SCHEMBL47638 0.78 CHRM2 (0.40) HDAC4CYP2C19KDM4ETSHRALDH1A1
SCHEMBL18588761 0.74 POLR1A (0.40) HDAC4CYP2C19KDM4EALDH1A1P2RX7
SCHEMBL14707958 0.73 KDM4E (0.36) KDM4ETSHRALDH1A1CYP3A4MAPT
SCHEMBL16522002 0.72 KDM4E (0.36) CYP2C19KDM4ETSHRALDH1A1CYP3A4
SCHEMBL14707959 0.71 KDM4E (0.36) KDM4ETSHRALDH1A1CYP3A4MAPT
SCHEMBL18078985 0.71 CYP1A2 (0.45) KDM4EALDH1A1ALOX15HSD17B10KMT2A
SCHEMBL47635 0.70 CYP2C19 (0.40) CYP2C19KDM4ETSHRALDH1A1CYP3A4
SCHEMBL18078993 0.68 TMEM97 (0.38) KDM4ETSHRALDH1A1CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9919033-B2 Dry growth hormone composition transiently linked to a polymer carrier ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) 2018-03-20 US disclosed
US-20170112939-A1 PREVENTION AND TREATMENT OF OCULAR CONDITIONS Ascendis Pharma Ophthamology Division A/S (DK) 2017-04-27 US disclosed
US-20170100490-A1 Prodrug Comprising a Drug Linker Conjugate ASCENDIS PHARMA A/S (DK) 2017-04-13 US disclosed
US-20170056477-A1 Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) 2017-03-02 US disclosed
US-9511122-B2 Dry growth hormone composition transiently linked to a polymer carrier ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) 2016-12-06 US disclosed
US-20160206702-A1 PEGylated Recombinant Human Growth Hormone Compounds ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) 2016-07-21 US disclosed
US-9272048-B2 PEGylated recombinant human growth hormone compounds ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) 2016-03-01 US disclosed
US-20150290337-A1 DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT ASCENDIS PHARMA INC. 2015-10-15 US disclosed
US-20150057221-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE ASCENDIS PHARMA AS (DK) 2015-02-26 US disclosed
US-20150010634-A1 PREVENTION AND TREATMENT OF OCULAR CONDITIONS Ascendis Pharma Ophthamology Division A/S (DK) 2015-01-08 US disclosed
US-8906847-B2 Prodrug comprising a drug linker conjugate ASCENDIS PHARMA A/S (DK) 2014-12-09 US disclosed
US-20140323402-A1 Protein Carrier-Linked Prodrugs Ascendis Phama A/S (DK) 2014-10-30 US disclosed
US-20140296257-A1 High-Loading Water-Soluable Carrier-Linked Prodrugs ASCENDIS PHARMA A/S (DK) 2014-10-02 US disclosed
US-20140243254-A1 Polymeric Hyperbranched Carrier-Linked Prodrugs ASCENDIS PHARMA A/S (DK) 2014-08-28 US disclosed
US-20120322721-A1 DRY GROWTH HORMONE COMPOSITION TRANSIENTLY LINKED TO A POLYMER CARRIER ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) 2012-12-20 US disclosed
US-20120156259-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels ASCENDIS PHARMA A/S (DK) 2012-06-21 US disclosed
US-20120058084-A1 Interferon Alpha Carrier Prodrugs ASCENDIS PHARMA AS (DK) 2012-03-08 US disclosed
US-20110112021-A1 PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS ASCENDIS PHARMA AS (DK) 2011-05-12 US disclosed
US-20110053848-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE ASCENDIS PHARMA AS (DK) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296257-A1 High-Loading Water-Soluable Carrier-Linked Prodrugs ABCB11, SLCO1B1, SLC7A1 HDAC4 2042/4885CYP2C19 96/4885KDM4E 3887/4885
US-20170112939-A1 PREVENTION AND TREATMENT OF OCULAR CONDITIONS PDE6C, ALDH1A2, UACA HDAC4 358/4885CYP2C19 2195/4885KDM4E 4186/4885
US-20120322721-A1 DRY GROWTH HORMONE COMPOSITION TRANSIENTLY LINKED TO A POLYMER CARRIER GHRHR, GHSR, GCG HDAC4 3183/4885CYP2C19 1405/4885KDM4E 2150/4885
US-20120156259-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels PLG, PHYKPL, PLOD3 HDAC4 1281/4885CYP2C19 1221/4885KDM4E 1756/4885
US-20150290337-A1 DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT ADAMTS13, ADAMTS5, TNF HDAC4 2725/4885CYP2C19 560/4885KDM4E 4331/4885
US-20150057221-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE H1-0, H1-3, H1-2 HDAC4 1085/4885CYP2C19 212/4885KDM4E 1446/4885
US-20170056477-A1 Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier GHRHR, GHSR, GCG HDAC4 3183/4885CYP2C19 1405/4885KDM4E 2150/4885
US-20170100490-A1 Prodrug Comprising a Drug Linker Conjugate H1-0, H1-3, H1-2 HDAC4 1085/4885CYP2C19 212/4885KDM4E 1446/4885
US-20110112021-A1 PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS GHRHR, GHITM, GHSR HDAC4 1990/4885CYP2C19 4238/4885KDM4E 3989/4885
US-20160206702-A1 PEGylated Recombinant Human Growth Hormone Compounds GHRHR, GHITM, GHSR HDAC4 1990/4885CYP2C19 4238/4885KDM4E 3989/4885
US-20140243254-A1 Polymeric Hyperbranched Carrier-Linked Prodrugs P4HA1, CYP8B1, PAH HDAC4 1870/4885CYP2C19 62/4885KDM4E 3467/4885
US-20110053848-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE H1-0, H1-3, H1-2 HDAC4 1070/4885CYP2C19 212/4885KDM4E 1429/4885
US-20140323402-A1 Protein Carrier-Linked Prodrugs SLC6A7, PRAP1, PELP1 HDAC4 4327/4885CYP2C19 1367/4885KDM4E 4594/4885
US-20150010634-A1 PREVENTION AND TREATMENT OF OCULAR CONDITIONS PDE6C, ALDH1A2, UACA HDAC4 358/4885CYP2C19 2195/4885KDM4E 4186/4885
US-20120058084-A1 Interferon Alpha Carrier Prodrugs IFNG, IFNAR1, IRF3 HDAC4 2967/4885CYP2C19 98/4885KDM4E 4661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.